Pharmaceutical and Biotech Public Relations
Agencourt Bioscience Corporation
HTG
InnoCentive
Business and Financial Services Public Relations
Business Software and Solutions Public Relations
Cleantech and Green Public Relations
Consumer Public Relations
Data Center and IT Operations Public Relations
Emerging Technology Public Relations
Healthcare IT Public Relations
Medical Device and Diagnostics Public Relations
Networking, Wireless and Telecom Public Relations
Security Public Relations
Software Development and Open Source Public Relations
PR Agency Case Study for Pharmaceutical and Biotech Public Relations

Pharmaceutical and Biotech Public Relations

Agencourt Bioscience Corporation
Agencourt Bioscience Corporation provides genomics services and nucleic acid purification reagents to biotech and pharmaceutical companies, academic institutions and government facilities. Its Discovery Solutions suite of services span genomic, functional genomic and proteomic fields that aid biotechnology and pharmaceutical companies improve the efficiency of their drug discovery pipelines. Agencourt’s GLP-compliant facility is located in Beverly, Mass., and is online at www.agencourt.com. Agencourt was started in July 2000 offering nucleic acid purification reagents based on its patented Solid Phase Reversible Immobilization (SPRI™) technology. Agencourt’s co-chief scientific officers were involved in the development of SPRI technology at the Whitehead Institute as part of the Human Genome Project. Agencourt quickly expanded to offer a suite of sequencing services based on SPRI nucleic acid purification technology. SPRI purification technology was used to sequence over a third of the human genome and has been adopted by many of the top genomic centers. Most recently, Agencourt was recognized as a leading sequencing center by the NIH and will participate in the sequencing of genomes of organisms identified as having biomedical importance.

HTG
High Throughput Genomics, Inc., (HTG), is a provider of transcriptomic technology and services. HTG’s technology opens a new era of drug discovery and allows companies to identify new drug compounds, quickly eliminate less promising compounds and bring new drugs to market faster. HTG is the first company to commercialize this technology. HTG is online at www.htgenomics.com.

InnoCentive
The leader in on-demand innovation.


"I felt compelled to write you this morning because your firm has had one heck of an impact on my company and I thought you deserved to know. I'm not an easy client to please, nor an easy person to work with daily, so that alone should say something about how special your employees truly are. Thank you for giving JobKite a sense of pride we have been longing for."

Heather Galler,
CEO,
JobKite

 


US
UK
SWEDEN